Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma

摘要: Background/Aims: Programmed death receptor 1 (PD-1) is a promising new target for treatment of patients with hepatocellular carcinoma (HCC). A high expression level programmed death-ligand (PD-L1) possible prognostic indicator poor outcome in other malignancies. Here, we investigated the clinical significance PD-1 and PD-L1 HCC. Methods: We enrolled HCC who underwent surgical resection at Severance Hospital between 2012 2017 levels tissues (tPD-L1) PD-L1/PD-1 serum (sPD-L1/sPD-1). also aimed to determine whether correlated histological features. Results: total 72 patient samples were analyzed. The median sPD-L1 sPD-1 25.72 341.44 pg/mL, respectively. positive correlation was detected tPD-L1 (R2=0.426, P 50% reduction observed immediately after nivolumab administration. However, not associated directly prognosis advanced HCC. Conclusions: results demonstrated that changed according immunotherapy. no significant association detected. (J Liver Cancer 2019;19:108-116)